374777-77-2

Basic information

• Product Name: L-GlutaMic acid, N-[4-[1-[(2,4-diaMino-6-pteridinyl)Methyl]-3-butyn-1-yl]benzoyl]-, 1,5-diMethyl ester
• Synonyms: L-GlutaMic acid, N-[4-[1-[(2,4-diaMino-6-pteridinyl)Methyl]-3-butyn-1-yl]benzoyl]-, 1,5-diMethyl ester;(2S)-dimethyl 2-(4-(1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl)benzamido)pentanedioate
• CAS NO: 374777-77-2
• Molecular Formula: C₂₅H₂₇N₇O₅
• Molecular Weight: 505.52578
• Mol File: 374777-77-2.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: L-GlutaMic acid, N-[4-[1-[(2,4-diaMino-6-pteridinyl)Methyl]-3-butyn-1-yl]benzoyl]-, 1,5-diMethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: L-GlutaMic acid, N-[4-[1-[(2,4-diaMino-6-pteridinyl)Methyl]-3-butyn-1-yl]benzoyl]-, 1,5-diMethyl ester(374777-77-2)
• EPA Substance Registry System: L-GlutaMic acid, N-[4-[1-[(2,4-diaMino-6-pteridinyl)Methyl]-3-butyn-1-yl]benzoyl]-, 1,5-diMethyl ester(374777-77-2)

Safety Data

• Hazardous Substances Data: 374777-77-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research and Development:
L-GlutaMic acid, N-[4-[1-[(2,4-diaMino-6-pteridinyl)Methyl]-3-butyn-1-yl]benzoyl]-, 1,5-diMethyl ester is used as a research compound for exploring its potential in pharmaceutical applications. The presence of the pteridine structure, which is involved in various biological pathways, and the benzoyl group, known for its pharmacological effects, makes L-GlutaMic acid, N-[4-[1-[(2,4-diaMino-6-pteridinyl)Methyl]-3-butyn-1-yl]benzoyl]-, 1,5-diMethyl ester a candidate for further investigation into its medicinal properties.
Used in Drug Design and Synthesis:
In the field of medicinal chemistry, L-GlutaMic acid, N-[4-[1-[(2,4-diaMino-6-pteridinyl)Methyl]-3-butyn-1-yl]benzoyl]-, 1,5-diMethyl ester is utilized as a building block or a template in the design and synthesis of new drugs. Its unique structure may offer novel mechanisms of action or improved pharmacokinetic properties, contributing to the development of innovative therapeutic agents.
Used in Biochemical Studies:
L-GlutaMic acid, N-[4-[1-[(2,4-diaMino-6-pteridinyl)Methyl]-3-butyn-1-yl]benzoyl]-, 1,5-diMethyl ester is also used in biochemical studies to understand its interactions with biological systems. The pteridine component may play a role in enzyme activity, receptor binding, or other cellular processes, providing insights into its potential therapeutic applications.
Used in Diagnostic Applications:
Given its structural features, L-GlutaMic acid, N-[4-[1-[(2,4-diaMino-6-pteridinyl)Methyl]-3-butyn-1-yl]benzoyl]-, 1,5-diMethyl ester may be employed in the development of diagnostic tools, such as imaging agents or biosensors, that leverage its chemical properties for detecting or monitoring diseases.

Upstream product

• 23150-65-4 L-glutamic dimethyl ester hydrochloride 
• 146464-93-9 4-(1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl)benzoic acid 
• 146464-91-7 methyl-4-(2-((2,4-diaminopteridin-6-yl)methyl)-1-methoxy-1-oxopent-4-yn-2-yl)benzoate 
• 146464-92-8 4-(2-carboxy-1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl)benzoic acid 
• 146464-90-6 α-propargylhomoterephthalic acid dimethyl ester 
• 1548618-47-8 10-propargyl-10-carbomethoxy-4-deoxy-4-amino-10-deazapteroic acid methyl ester hydrobromide salt 
• 6525-53-7 L-glutamic acid dimethyl ester 
• 1445586-50-4 10-propargyl-10-carboxy-4-deoxy-4-amino-10-deazapteroic acid sodium salt 
• 52787-14-1 methyl 4-(2-methoxy-2-oxoethyl)benzoate 

Downstream Products

• 146464-95-1 pralatrexate 
• 1320211-82-2 C₂₅H₂₇N₇O₅ 
• 1320211-79-7 C₂₅H₂₇N₇O₅ 

Relevant articles and documents

IMPROVED PROCESS FOR THE PREPARATION OF PRALATREXATE

An improved process for the preparation of Pralatrexate which is less hazardous. The invention further relates to novel intermediates and process thereof useful for the preparation of Pralatrexate. The present invention also relates to a substantially pure Pralatrexate and a process for obtaining the same in high yield.

IMPROVED PROCESS FOR THE PREPARATION OF PRALATREXATE

An improved process for the preparation of Pralatrexate which is less hazardous. The invention further relates to novel intermediates and process thereof useful for the preparation of Pralatrexate. The present invention also relates to a substantially pure Pralatrexate and a process for obtaining the same in high yield.

PROCESS FOR PREPARATION OF AN ANTIFOLATE AGENT

The specification relates to a process for preparation of an antifolate compound of formula 7, such as Pralatrexate. Also, disclosed are intermediates and processes for preparation of intermediates useful in the preparation of the antifolate compound. The substituents Y, Z, R, R1 and R2 are as described herein. The processes and intermediates can provide an alternate route to the synthesis of the antifolate compound. Further, the processes can help to avoid distillation or evaporation of high boiling point solvents, chromatographic purification and use of hazardous combination of solvents; and can also provide a product having high purity, all of which are desirable for synthesis on a large scale.

Optically Pure Diastereomers of 10-Propargyl-10-Deazaaminopterin and Methods of Using Same

The present invention relates to diastereomers of 10-propargyl-10-deazaminopterin, compositions comprising optically pure diastereomers of 10-propargyl-10-deazaminopterin, in particular the two (R,S) diastereomers about the C10 position. Methods of preparation of these diastereomers, compositions containing them, and their use for the treatment of conditions related to inflammatory disorders and cancer are also disclosed.

Treatment of T-cell lymphoma using 10-propargyl-10-deazaaminopterin

T cell lymphoma is treated by administering to a patient suffering from T cell lymphoma a therapeutically effective amount of 10-propargyl-10-deazaaminopterin. Remission is observed in human patients, even with drug resistant T cell lymphoma at weekly dosages levels as low as 30 mg/m2. In general, the 10-propargyl-10-deazaaminopterin is administered in an amount of from 30 to 275 mg/m2 per dose.

Combinations of 10-propargyl-10-deazaaminopterin and taxols and methods of using same in the treatment of tumors

Preliminary clinical studies in humans have now been done which show both the efficacy of 10-propargyl-10dAM and a preferred dosage schedule for such treatments. In addition, it has now been determined that combinations of 10-propargyl-10-deazaaminopterin

Purified compositions of 10-propargyl-10-deazaaminopterin and methods of using same in the treatment of tumors

PCT No. PCT/US97/11982 Sec. 371 Date Mar. 8, 1999 Sec. 102(e) Date Mar. 8, 1999 PCT Filed Jul. 16, 1997 PCT Pub. No. WO98/02163 PCT Pub. Date Jan. 22, 1998Highly purified 10-propargyl-10-deazaaminopterin (10-propargyl-10dAM) compositions tested in xenogra